Flibanserin Patent Expiration

Flibanserin is Used for treating hypoactive sexual desire disorder (HSDD). It was first introduced by Sprout Pharmaceuticals Inc in its drug Addyi on Aug 18, 2015.


Flibanserin Patents

Given below is the list of patents protecting Flibanserin, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Addyi US7151103 Method of treating female hypoactive sexual desire disorder with flibanserin May 09, 2028 Sprout Pharms
Addyi US8227471 Treating sexual desire disorders with flibanserin May 09, 2023

(Expired)

Sprout Pharms
Addyi US9468639 Treating sexual desire disorders with flibanserin Oct 16, 2022

(Expired)

Sprout Pharms
Addyi US7420057 Stable polymorph of flibanserin Aug 01, 2022

(Expired)

Sprout Pharms



Flibanserin's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List